<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02086929</url>
  </required_header>
  <id_info>
    <org_study_id>039(C)SC11063</org_study_id>
    <nct_id>NCT02086929</nct_id>
  </id_info>
  <brief_title>Trazodone Once a Day in Major Depression Disorder</brief_title>
  <official_title>A Randomized, Double-blind Study Comparing the Efficacy and Safety of Trazodone OAD and Venlafaxine XR in the Treatment of Patients With Major Depressive Disorder.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aziende Chimiche Riunite Angelini Francesco S.p.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aziende Chimiche Riunite Angelini Francesco S.p.A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objective is to evaluate the efficacy and safety of trazodone OAD vs venlafaxine
      extended release (venlafaxine XR) after an 8-week treatment period in patients with major
      depressive disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, venlafaxine-controlled, double-blind, parallel design study consists of a
      Pre-Treatment Phase (screening, wash-out) and a double-blind Treatment Phase (randomization
      to trazodone OAD or to venlafaxine XR, treatment for 8 weeks and tapering for 1 to 3 weeks).
      During the Pre-Treatment Phase, patients who sign an informed consent form will undergo
      initial screening. Potential candidates will be instructed to discontinue antidepressants or
      prohibited medications (wash-out) for a period specific to taper schedule (based on 5
      elimination half-lives of the used medication). On the last day of the Pre-Treatment Phase,
      patients will be evaluated for the final eligibility, and those qualified will be randomly
      allocated in a 1:1 proportion to trazodone OAD 300 mg/day (1 week of tapering with trazodone
      OAD 150 mg/day) or to venlafaxine XR 75 mg/day once daily. After 3 and 5 weeks of treatment,
      subjects will be evaluated for the response. For non responding patients dose increases (in
      increments of 75 mg/day) will be done till to reach the maximum of 225 mg/day for venlafaxine
      XR and 450 mg/day for trazodone OAD. Patients non responding to treatment at the final visit
      will have their study medication tapered from 1 to 3 weeks, according to the maximum dose
      reached during the study. In order to prevent relapse of depression symptoms, responders at
      the final visit may continue the treatment. In this case, an unblinded third party Dispenser
      will open the treatment code and will prescribe the same medication taken by the patients
      during the trial, according to the formulation available on the market.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale (HAMD) score</measure>
    <time_frame>Day 56</time_frame>
    <description>Mean change from baseline (Day 0) in HAMD score at Day 56.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS) score</measure>
    <time_frame>Day 56</time_frame>
    <description>Mean change from baseline (Day 0) in MADRS score at Day 56.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI) Severity of Illness score</measure>
    <time_frame>Day 56</time_frame>
    <description>CGI-Severity of Illness improvement at Day 56.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI) Global improvement score</measure>
    <time_frame>Day 56</time_frame>
    <description>CGI-Global improvement at Day 56.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders</measure>
    <time_frame>Day 56</time_frame>
    <description>Rate of patients with a 50% decrease with respect to baseline on the HAMD score at Day 56.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with remission</measure>
    <time_frame>Day 56</time_frame>
    <description>Rate of patients with a HAMD score &lt;or= at Day 56.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of trazodone OAD compared to venlafaxine XR</measure>
    <time_frame>11 weeks</time_frame>
    <description>Safety and tolerability will be assessed through adverse events monitoring, physical examinations and monitoring of vital signs, body weight, clinical laboratory tests, ECG.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">364</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Trazodone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg/day for 8 weeks (including 1 week 150 mg/day of dose-titration). After 3 and 5 weeks of treatment, non responders will have dose increases (in increments of 75 mg/day) till to reach the maximum of 450 mg/day.
Dosage form: capsule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Venlafaxine XR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>75 mg/die for 8 weeks. After 3 and 5 weeks of treatment, non responders will have dose increases (in increments of 75 mg/day) till to reach the maximum of 225 mg/day.
Dosage form: capsule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trazodone</intervention_name>
    <arm_group_label>Trazodone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine</intervention_name>
    <arm_group_label>Venlafaxine XR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  men and women 18-75 years of age (limits included) with no limitation of race;

          -  outpatients;

          -  major depressive disorder according to DSM-IV criteria as assessed using the MINI
             International Neuropsychiatric Interview;

          -  17-item HAMD score &gt; 18 at both screening and baseline visits with a decrease not
             exceeding 20% between screening and baseline;

          -  symptoms of depression for at least one month before study entry (screening visit);

          -  legally capable to give their consent to participate the study, and available to sign
             and date the written informed consent prior to the inclusion in the study;

          -  women of childbearing potential must agree not to start a pregnancy from the signature
             of the informed consent up to 30 days after the last administration of the
             investigational product.

        Exclusion Criteria:

          -  participation in another trial involving any investigational drug during the past 60
             days;

          -  known hypersensitivity to venlafaxine or trazodone or their excipients;

          -  use of venlafaxine or trazodone within the previous six months;

          -  acute, or chronic, or recurrent medical conditions that might affect/jeopardize the
             study results;

          -  significant liver disease, defined as active hepatitis or elevated liver enzymes &gt; 3
             times the upper boundary of the normal range;

          -  significant renal disease, defined as urea and/or creatinine &gt; 3 times the upper
             boundary of the normal range

          -  myocardial infarction within 6 months prior to start of the double blind treatment;

          -  positive present history of glaucoma;

          -  history of risk factors for Torsade de Pointes, such as heart failure, cardiac
             arrhythmias, bradycardia, cardiac conduction abnormalities, family history of long QT
             syndrome, cardiac hypertrophy, cardiomyopathy, chronic cardiac insufficiency;

          -  values of electrolytes (sodium, potassium, calcium, magnesium, chloride) outside the
             normal laboratory range and judged clinically relevant by the Investigator;

          -  concomitant treatment with drugs known for QT prolongation, or with drugs producing
             hypokalemia, or diuretics;

          -  QTcF values higher than 450 msec in the ECG performed at the screening;

          -  history of major depression resistant to medical treatments (previous failure to
             respond to two consecutive antidepressants of different classes used for a sufficient
             length of time at appropriate doses);

          -  history of seizure events other than a single childhood febrile seizure;

          -  history of alcohol or psychoactive substance abuse or addiction (except caffeine or
             nicotine) during the last year as defined by DSM-IV criteria;

          -  positive urine drug screen for CNS-active drugs (cocaine, opioids, amphetamines and
             cannabinoids) at Visit 1 (screening);

          -  acute risk of suicide (HAMD, criterion 3 with a value &gt; 3);

          -  presence of any primary psychiatric disorder other than major depression;

          -  history or presence of bipolar disorder, any psychotic disorder, mental disorder due
             to general medical conditions;

          -  pregnancy, lactation, or female with a positive urine pregnancy test result at Visit 1
             (Screening);

          -  electroconvulsive therapy (ECT) within 30 days prior to the screening visit;

          -  use of antipsychotic drugs within two months prior to the baseline visit (Visit 2);

          -  use of any anxiolytic or sedative hypnotic drug within seven days prior to the
             baseline (Visit 2) and during the study. Exception is stable low doses of
             benzodiazepines for insomnia (if taken by the patient more than two weeks before the
             Treatment Phase);

          -  use of any psychotropic drug or substance with central nervous system effects within
             seven days prior to the baseline visit (Visit 2);

          -  use of any non-psychotropic drug with psychotropic effects (e.g. alpha-adrenergic
             blockers) within seven days prior to the baseline visit (visit 2), unless a stable
             dose of the drug has been maintained for at least one month (three months for thyroid
             or hormonal medications) before the baseline visit (visit 2);

          -  concomitant treatment with CYP3A4 inhibitors (e.g. ketoconazole, ritonavir,
             indinavir);

          -  hyperthyroidism, even if pharmacologically corrected;

          -  start or discontinuation of psychotherapy within 6 weeks prior to screening;

          -  clinically significant abnormalities on physical examination, vital signs, ECG,
             laboratory tests at the screening visit;

          -  high blood pressure (supine systolic blood pressure &gt; 160 mmHg or supine diastolic
             blood pressure &gt; 90 mmHg) at screening or baseline, either untreated or under
             treatment with antihypertensives

          -  inability to comply with the protocol requirements, instructions and study-related
             restrictions; e.g. uncooperative attitude, inability to return for study-visits, and
             improbability of completing the clinical study;

          -  vulnerable subjects (e.g. persons kept in detention);

          -  if subject is the Investigator or his/her deputies, first grade relative, research
             assistant, pharmacist, study coordinator, other staff of relative thereof directly
             involved in the conduct of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filippo Bogetto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neuroscience University of Turin - Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute für Psychosomatik</name>
      <address>
        <city>Vienna</city>
        <zip>1010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRAGTIS, s.r.o.</name>
      <address>
        <city>Praha 2</city>
        <state>Praha</state>
        <zip>12000</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatry Trial, s.r.o.</name>
      <address>
        <city>Praha 5</city>
        <state>Praha</state>
        <zip>15800</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MEDICAL SERVICES PRAGUE, s.r.o.</name>
      <address>
        <city>Praha 6</city>
        <state>Praha</state>
        <zip>160 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neuropsychiatrie s.r.o.</name>
      <address>
        <city>Praha 6</city>
        <state>Praha</state>
        <zip>160 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Anne, s.r.o.</name>
      <address>
        <city>Brno-mesto</city>
        <zip>60200</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUPERVIZE, s.r.o.</name>
      <address>
        <city>Kutna Hora</city>
        <zip>284 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BIALBI s.r.o.</name>
      <address>
        <city>Litomerice</city>
        <zip>41201</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Olomouc, Klinika Psychiatrie</name>
      <address>
        <city>Olomouc</city>
        <zip>77 900</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUDr. Eva Soukupová-Psychiatrická praxe, s.r.o.</name>
      <address>
        <city>Plzeň</city>
        <zip>301 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZZ- MUDr. Jaroslav Hronek, psychiatrická ambulance</name>
      <address>
        <city>Plzeň</city>
        <zip>301 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOPI di Psichiatria Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele, Presidio &quot;Gaspare Rodolico&quot;</name>
      <address>
        <city>Catania</city>
        <zip>95100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Psichiatrica Nuovo Ospedale S. Salvatore Università degli Studi del L'Aquila</name>
      <address>
        <city>L'Aquila</city>
        <zip>67100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria della Misericordia Unità di Degenza Psichiatrica-SPDC</name>
      <address>
        <city>Perugia</city>
        <zip>06132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Sant'Andrea Università La Sapienza Unità Operativa Complessa di Psichiatria</name>
      <address>
        <city>Rome</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOUS-Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria alle Scotte Clinica Psichiatrica Universitaria</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurosciences University of Turin</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quantum Medical Center Srl</name>
      <address>
        <city>Bucharest</city>
        <zip>RO-011426</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul clinic de psihiatrie &quot;Prof. Dr. Al. Obregia&quot;/Sectia 13</name>
      <address>
        <city>Bucharest</city>
        <zip>RO-041914</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Psihiatrie &quot;Prof. Dr. Al. Obregia&quot;/Sectia 1</name>
      <address>
        <city>Bucharest</city>
        <zip>RO-041914</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinc de Urgenta Militar &quot;Dr. Stefan Odobleja&quot;, Craiova</name>
      <address>
        <city>Craiova</city>
        <zip>RO-200530</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spital Clinic de Psihiatrie SOCOLA / Iasi</name>
      <address>
        <city>Iasi</city>
        <zip>RO-700282</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul de Psihiatrie &quot;Dr. Gh.Preda&quot; Sibiu</name>
      <address>
        <city>Sibiu</city>
        <zip>RO-550082</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinc Judetean Mures, Centrul de Sanatate Mintala</name>
      <address>
        <city>Targu Mures</city>
        <zip>RO-540096</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatricka ambulancia</name>
      <address>
        <city>Bratislava</city>
        <zip>81107</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MENTUM, s.r.o.</name>
      <address>
        <city>Bratislava</city>
        <zip>82007</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EPAMED, s.r.o.</name>
      <address>
        <city>Kosice</city>
        <zip>4000</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatricka nemocnica</name>
      <address>
        <city>Michalovce</city>
        <zip>7101</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psycholine, s.r.o.</name>
      <address>
        <city>Rimavska Sobota</city>
        <zip>97901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatricke oddelenie, NsP sv Barbory Roznava</name>
      <address>
        <city>Roznava</city>
        <zip>4801</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigacion y Asistencia Psiquiatrica - IIAP</name>
      <address>
        <city>Madrid</city>
        <zip>28002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>Italy</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.angelinipharma.com</url>
    <description>Sponsor's website</description>
  </link>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2014</study_first_submitted>
  <study_first_submitted_qc>March 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2014</study_first_posted>
  <last_update_submitted>December 29, 2015</last_update_submitted>
  <last_update_submitted_qc>December 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Trazodone</keyword>
  <keyword>Venlafaxine</keyword>
  <keyword>Major depressive disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
    <mesh_term>Trazodone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

